Cite
HARVARD Citation
Colclough, N. et al. (n.d.). Preclinical comparison of the blood brain barrier (BBB) permeability of osimertinib (AZD9291) with other irreversible next generation EGFR TKIs. European journal of cancer. pp. S28-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Colclough, N. et al. (n.d.). Preclinical comparison of the blood brain barrier (BBB) permeability of osimertinib (AZD9291) with other irreversible next generation EGFR TKIs. European journal of cancer. pp. S28-. [Online].